$101.10
0[0.00%]
At close: Apr 23
$101.10
0[0.00%]
PreMarket: 4:20PM EDT
Latest News for Glaukos Stock (NYSE:GKOS)
Glaukos Stock (NYSE: GKOS)
Categories: All
Thursday, April 11, 2024
Monday, April 08, 2024
Wednesday, April 03, 2024
- Glaukos shares are trading higher after the US Centers for Medicare and Medicaid Services assigned a permanent J-code for iDose TR.Benzinga Newsdesk - Apr 3, 2024, 11:48AM
- Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On WednesdayAvi Kapoor - Apr 3, 2024, 10:31AM
- Stifel Reiterates Buy on Glaukos, Maintains $110 Price TargetBenzinga Newsdesk - Apr 3, 2024, 8:50AM
- U.S. Centers For Medicare And Medicaid Services Has Assigned Unique, Permanent Healthcare Common Procedure Coding System J-code For Glaukos' iDose TR (Travoprost Intracameral Implant) 75 mcg For Reduction Of Intraocular PressureBenzinga Newsdesk - Apr 3, 2024, 7:25AM
Monday, March 25, 2024
Friday, March 22, 2024
Thursday, February 22, 2024
Wednesday, February 21, 2024
- Glaukos: Q4 Earnings InsightsBenzinga Insights - Feb 21, 2024, 4:15PM
- Glaukos Reaffirms 2024 Net Sales Guidance Of $350M-$360M, Est $356.29MBenzinga Newsdesk - Feb 21, 2024, 4:12PM
- Glaukos Q4 Adj EPS $(0.63) Misses $(0.55) Estimate, Sales $82.36M Beat $78.69M EstimateBenzinga Newsdesk - Feb 21, 2024, 4:07PM
- Earnings Scheduled For February 21, 2024Benzinga Insights - Feb 21, 2024, 5:09AM
Friday, February 16, 2024
Tuesday, January 09, 2024
- Glaukos shares are trading higher after the company reported preliminary Q4 and FY23 net sales guidance above estimates. Also, the company reaffirmed its FY24 net sales guidance.Benzinga Newsdesk - Jan 9, 2024, 10:57AM
- Glaukos Reaffirms FY24 Net Sales Guidance Range Of $350M-$360M Versus Consensus Of $354.59MBenzinga Newsdesk - Jan 9, 2024, 7:09AM
- Glaukos Reports Preliminary Q4 FY23 Net Sales Of Over $81M And Over $313M For FY23 Versus Consensus Of $76.69M And $309.05M, RespectivelyBenzinga Newsdesk - Jan 9, 2024, 7:08AM
Friday, December 29, 2023
Friday, December 22, 2023
Thursday, December 21, 2023
- Glaukos shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $66 to $91.Benzinga Newsdesk - Dec 21, 2023, 2:11PM
- Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': AnalystPriya Nigam - Dec 21, 2023, 11:48AM
- Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For ThursdayAvi Kapoor - Dec 21, 2023, 7:36AM
- Unveiling 7 Analyst Insights On GlaukosBenzinga Insights - Dec 21, 2023, 7:00AM
- JP Morgan Upgrades Glaukos to Overweight, Raises Price Target to $91Benzinga Newsdesk - Dec 21, 2023, 5:30AM
Friday, December 15, 2023
- Glaukos shares are trading higher after the company recently announced FDA approval of iDose TR and issued preliminary 2024 net sales guidance above estimates.Benzinga Newsdesk - Dec 15, 2023, 3:15PM
- iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says AnalystVandana Singh - Dec 15, 2023, 1:49PM
Thursday, December 14, 2023
- FDA Approves Glaukos' Eye Implant To Treat Eye Pressure In Glaucoma PatientsVandana Singh - Dec 14, 2023, 8:53AM
- Glaukos shares are trading higher after the company announced FDA approval of iDose TR and issued preliminary 2024 net sales guidance above estimates.Benzinga Newsdesk - Dec 14, 2023, 8:52AM
- Glaukos Introduces Preliminary FY24 Sales Guidance Of $350M-$360M Versus Consensus Of $348.68MBenzinga Newsdesk - Dec 14, 2023, 7:10AM
- Glaukos Reaffirms Its FY23 Sales Guidance Of $307M-$310M Versus Consensus Of $309.09MBenzinga Newsdesk - Dec 14, 2023, 7:08AM
- The FDA Has Approved Glaukos' Single Administration Per Eye Of iDose TR (Travoprost Intracameral Implant) 75 Mcg, A Prostaglandin Analog Indicated For The Reduction Of Intraocular Pressure In Patients With Ocular Hypertension Or Open-angle GlaucomaBenzinga Newsdesk - Dec 14, 2023, 7:05AM
Monday, December 04, 2023
Tuesday, November 28, 2023
Wednesday, November 08, 2023
Thursday, November 02, 2023
Wednesday, November 01, 2023
- Glaukos Raises 2023 Net Sales Guidance From $304M-$308M To $307M-$310MBenzinga Newsdesk - Nov 1, 2023, 6:00PM
- Glaukos Q3 Adj EPS $(0.50) Beats $(0.55) Estimate, Sales $78.05M Beat $75.25M EstimateBenzinga Newsdesk - Nov 1, 2023, 4:51PM
- Earnings Scheduled For November 1, 2023Benzinga Insights - Nov 1, 2023, 7:19AM